RxDoctor Payments Data

Rajus Chopra, MD

Cardiovascular Disease · Holland, MINPI 1649632720

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 25 payments — averaging $67.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$559
  • Abiomed$274
  • Abbott$189
  • Medtronic$163
  • Heartflow, Inc.$111
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$107
  • plus $290 from 6 others

What the payments were for

  • Food & beverage$1,693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$83,409
Medicare patients
720
Services billed
1,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$308,839
XareltoRivaroxaban110$140,191
JardianceEmpagliflozin52$48,400
FarxigaDapagliflozin Propanediol59$41,114
EntrestoSacubitril/Valsartan30$40,064
Metoprolol Succinate302$8,627
Flecainide Acetate59$4,022
Atorvastatin Calcium123$2,672
Rosuvastatin Calcium131$2,604
Losartan Potassium114$1,913
Potassium Chloride38$1,716
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$1,679
Ranolazine ErRanolazine16$1,668
Amlodipine Besylate146$1,509
Carvedilol96$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$308,839266 claims
Johnson & JohnsonXarelto$25$140,191110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →